Skip to main content
. 2022 Dec 1;22:458. doi: 10.1186/s12890-022-02190-w

Table 2.

Clinical characteristics of patients (N = 122)

Cohort
(N = 122)
Groups(%) P
COPD
(N = 61)
Non-COPD
(N = 61)
Age 0.230
median 66 67 66
range 45–89 50–83 45–89
Sex 0.680
Male 116(95.1) 59(96.7) 57(93.4)
Female 6(4.9) 2(3.3) 4(6.6)
Smoking history 0.073
Never-smokers 36(29.5) 13(21.3) 23(37.7)
Ever-smokers 86(70.5) 48(78.7) 38(62.3)
Histology 0.053
Adenocarcinoma 48(39.4) 19(31.1) 29(47.5)
Squamous 67(54.9) 40(65.6) 27(44.3)
Others 7(5.7) 2(3.3) 5(8.2)
ECOG performance status 0.752
0–1 120(98.4) 60(98.4) 60(98.4)
2–3 2(1.6) 1(1.6) 1(1.6)
Genetic profile 0.037
EGFR 4(3.3) 1(1.6) 3(4.9)
KRAS 7(5.7) 1(1.6) 6(9.8)
Others 3(2.5) 1(1.6) 2(3.3)
Negative 36(29.5) 14(23.0) 22(36.1)
NA 72(59.0) 44(72.1) 27(44.3)
Fibrosis score 0.638
0 100(82.0) 49(80.3) 51(83.6)
≥1 22(18.0) 12(19.7) 10(16.4)
Emphysema score 0.003
0 75(62.0) 29(47.5) 46(75.4)
≥ 1 47(38.0) 32(52.5) 15(24.6)
Baseline spirometry 0.642
DLco% predicted* 69.9(16.8) 65.9(15.2) 73.5(17.4)
irAE 0.211
No 90(73.8) 41(67.2) 49(80.3)
CIP 19(15.6) 11(18.0) 8(13.1)
Other irAE 13(10.7) 9(14.8) 4(6.6)
Treatment line 0.847
Adjuvant 21(17.2) 11(18.0) 10(16.4)
First-line 77(63.1) 38(62.3) 39(63.9)
Second-line 16(13.1) 7(11.5) 9(14.8)
Subsequent-line 8(6.6) 5(8.2) 3(4.9)

CIP, checkpoint inhibitors related pneumonitis; COPD, chronic obstructive pulmonary disease; DLco, diffusing capacity of the lung for carbon monoxide; ECOG, Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; NA, not available; irAE, immune-related adverse events

*Values in the table represent means (standard deviation)